PFS
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons-Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, Maurice Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip, Richard Hall, Oscar Juan-Vidal, Daniel Brungs, Shun Lu, Marina Garassino, Michael Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron Lisberg, Jacob Sands, TROPION-Lung01 Trial Investigators
J Clin Oncol 43(3) 260-272
PURPOSE: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC). METHODS: Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Objective response rate, duration of response, and safety were secondary end points. RESULTS: In total, 299 and 305 patients were randomly assigned to receive Dato-DXd or docetaxel, respectively. The median PFS was 4.4 months (95% CI, 4.2 to 5.6) with Dato-DXd and 3.7 months (95% CI, 2.9 to 4.2) with docetaxel (hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.91]; P = .004). The median OS was 12.9 months (95% CI, 11.0 to 13.9) and 11.8 months (95% CI, 10.1 to 12.8), respectively (HR, 0.94 [95% CI, 0.78 to 1.14]; P = .530). In the prespecified nonsquamous histology subgroup, the median PFS was 5.5 versus 3.6 months (HR, 0.63 [95% CI, 0.51 to 0.79]) and the median OS was 14.6 versus 12.3 months (HR, 0.84 [95% CI, 0.68 to 1.05]). In the squamous histology subgroup, the median PFS was 2.8 versus 3.9 months (HR, 1.41 [95% CI, 0.95 to 2.08]) and the median OS was 7.6 versus 9.4 months (HR, 1.32 [95% CI, 0.91 to 1.92]). Grade ≥3 treatment-related adverse events occurred in 25.6% and 42.1% of patients, and any-grade adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8.8% and 4.1% of patients, in the Dato-DXd and docetaxel groups, respectively. CONCLUSION: Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.
2 个 Figure · 6 个 KM 面板
FIG 2. PFS by treatment and key subgroups. Data cutoff: March 29, 2023. (A) Kaplan-Meier curves for PFS in the full analysis set, (B) HRs of PFS in key subgroups, (C) Kaplan-Meier curves for PFS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for PFS in patients with squamous histology. PFS was assessed by blinded independent central review. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. a Regardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; PFS, progression-free survival.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel D
Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. OS by treatment and key subgroups. Data cutoff: March 1, 2024. (A) Kaplan-Meier curves for OS in the full analysis set, (B) HRs of OS in key subgroups, (C) Kaplan-Meier curves for OS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for OS in patients with squamous histology. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. a Regardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; OS, overall survival.
FIG 3. · Panel A
Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. · Panel C
Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. · Panel D
Panel D 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。